AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a $16.5 million outlay. Eli Lilly and Boehringer Ingelheim’s ...

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...

As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025. It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 20 unusual trades. Delving into the details, we found 45% of traders were ...

The analyst continues to be positive on AbbVie, as he maintained his outperform (buy, in other words) recommendation on the stock and $215 per-share price target. Not surprisingly, according to ...

The Telugu Desam Party (TDP) has wrested the Kuppam Municipality from the YSR Congress Party (YSRCP) after more than three years. Kuppam has been a bastion of the TDP as Chief Minister N.

Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune ...